Ticker >

Everest Organics share price

Everest Organics Ltd.

BSE: 524790 SECTOR: Pharmaceuticals & Drugs  19k   171   10

136.25
-0.80 (-0.58%)
BSE: 17 May 04:01 PM

Price Summary

Today's High

₹ 139.95

Today's Low

₹ 136.1

52 Week High

₹ 161.7

52 Week Low

₹ 97.02

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

109 Cr.

Enterprise Value

159.22 Cr.

No. of Shares

0.8 Cr.

P/E

564.65

P/B

2.37

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  57.47

CASH

0.83 Cr.

DEBT

51.05 Cr.

Promoter Holding

74.15 %

EPS (TTM)

₹  0.24

Sales Growth

-8.5%

ROE

-0.39 %

ROCE

3.72%

Profit Growth

-115.93 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-8.5%
3 Year3.06%
5 Year10.29%

Profit Growth

1 Year-115.93%
3 Year-125.57%
5 Year-158.84%

ROE%

1 Year-0.39%
3 Year12.01%
5 Year21.17%

ROCE %

1 Year3.72%
3 Year14.58%
5 Year22.85%

Debt/Equity

1.1046

Price to Cash Flow

5.92

Interest Cover Ratio

1.02716422420305

CFO/PAT (5 Yr. Avg.)

1.94594205779117

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 74.15 0
Dec 2023 74.15 0
Sep 2023 74.15 0
Jun 2023 74.15 0
Mar 2023 74.15 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -58.0917246301349 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.94594205779117.
  • The company has a high promoter holding of 74.15%.

 Limitations

  • The company has shown a poor profit growth of -125.571210628193% for the Past 3 years.
  • The company has shown a poor revenue growth of 3.06212668531169% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 43.29 50.75 42.67 49.45 52.51
Total Expenditure 45.78 48.47 40.15 46.74 49.71
Operating Profit -2.49 2.28 2.52 2.71 2.8
Other Income 5.65 0.69 0.22 0.24 0.13
Interest 0.81 0.95 1.29 1.49 1.45
Depreciation 1.1 1.26 1.29 1.32 1.33
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.25 0.76 0.16 0.14 0.15
Tax -0.27 0.65 0.12 0.11 0.14
Profit After Tax 1.52 0.11 0.03 0.03 0.02
Adjusted EPS (Rs) 1.9 0.14 0.04 0.04 0.02

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 155.85 167.21 181.57 200.05 183.05
Total Expenditure 138.02 147.93 158.72 193.62 182.12
Operating Profit 17.83 19.28 22.84 6.43 0.93
Other Income 0.54 1.45 1.06 2.21 6.94
Interest 3.21 3.43 3.26 3.1 3.31
Depreciation 2.84 3.21 3.37 3.8 4.47
Exceptional Items 0 0 0 0 0
Profit Before Tax 12.33 14.09 17.27 1.74 0.09
Tax 4.82 3.2 3.56 0.6 0.27
Net Profit 7.51 10.9 13.72 1.14 -0.18
Adjusted EPS (Rs.) 9.39 13.62 17.14 1.43 -0.23

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 8 8 8 8 8
Total Reserves 17.98 26.2 38.58 38.8 38.21
Borrowings 4.66 4.61 5.81 10.99 11.65
Other N/C liabilities 5.54 7.47 5.63 7.66 6.4
Current liabilities 71.1 74.01 77.36 112.56 137.58
Total Liabilities 107.28 120.29 135.38 178 201.85
Assets
Net Block 38.5 39.04 43.57 48.97 56.57
Capital WIP 0.21 1.13 0.08 8.03 9.49
Intangible WIP 0 0 0 0 0
Investments 0.08 0.08 0.08 0.08 0.08
Loans & Advances 1.63 0.91 2.4 3.04 3.23
Other N/C Assets 0 0 0 0 0
Current Assets 66.85 79.14 89.25 117.88 132.48
Total Assets 107.28 120.29 135.38 178 201.85
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 12.33 14.09 13.72 1.14 -0.18
Adjustment 1.25 3.51 6.38 6.72 7.75
Changes in Assets & Liabilities -4.6 -7.89 -6.56 5.87 10.85
Tax Paid 0 0 0 0 0
Operating Cash Flow 8.98 9.71 13.53 13.74 18.42
Investing Cash Flow -5.36 -6.31 -11.82 -16.82 -15.6
Financing Cash Flow -2.71 -3.36 -2.05 2.07 -2.64
Net Cash Flow 0.91 0.04 -0.34 -1.01 0.18

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 74.15 74.15 74.15 74.15 74.15
bk advance research llp 2.80 2.80 2.80 2.80 2.80
hari krishna sk 0.07 0.07 0.07 0.07 0.07
kakarlapudi raju sitarama... 1.42 1.42 1.42 1.42 1.42
nadimpalli v raju 1.41 1.41 1.41 1.41 1.41
rajagopal rao rangineni 0.70 0.70 0.70 0.70 0.70
sk g parvathi 0.40 0.40 0.40 0.40 0.40
sri kakarlapudi krishna v... 0.68 3.94 3.94 3.94 3.94
sri kakarlapudi sirisha 1.35 1.35 1.35 1.35 1.35
sri kakarlapudi sri hari ... 18.75 15.49 15.49 15.49 15.49
veerat finance & investme... 46.57 46.57 46.57 46.57 46.57
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 25.85 25.85 25.85 25.85 25.85
everest organics limited ... 2.27 2.27 2.26 2.26 2.26

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ4FY20 10 Jul 2020

Company News

Everest Organics - Quaterly Results9 Feb 2024, 3:33PM Everest Organics - Quaterly Results9 Feb 2024, 3:33PM Everest Organics - Quaterly Results9 Feb 2024, 3:33PM Everest Organics informs about details of loss of certificate25 Jan 2024, 4:35PM Everest Organics informs about press release13 Nov 2023, 1:52PM Everest Organics informs about credit rating24 Aug 2023, 4:20PM Everest Organics informs about press release17 Aug 2023, 12:39PM Everest Organics informs about certificate7 Jul 2023, 5:40PM Everest Organics informs about compliances-certificate5 Apr 2023, 4:51PM Everest Organics - Quaterly Results14 Feb 2023, 3:19PM Everest Organics informs about disclosure on related party transactions 18 Nov 2022, 5:07PM Everest Organics - Quaterly Results11 Nov 2022, 1:21PM Everest Organics informs about board meeting 3 Nov 2022, 4:17PM Everest Organics informs about compliance certificate6 Oct 2022, 12:38PM Everest Organics informs about annual report2 Sep 2022, 4:09PM Everest Organics informs about AGM2 Sep 2022, 4:00PM Everest Organics - Quaterly Results9 Aug 2022, 2:09PM Everest Organics - Quaterly Results9 Aug 2022, 2:09PM Everest Organics - Quaterly Results9 Aug 2022, 2:09PM Everest Organics informs about loss of share certificate 21 Jul 2022, 2:02PM Everest Organics informs about demises of MD27 Apr 2022, 5:15PM Everest Organics informs about loss of share certificates14 Mar 2022, 5:17PM Everest Organics informs about disclosure2 Mar 2022, 4:42PM Everest Organics informs about newspaper publication5 Feb 2022, 3:39PM Everest Organics informs about compliance certificate 5 Jan 2022, 4:14PM Everest Organics informs about press release12 Oct 2021, 4:52PM Everest Organics develops new API to treat Covid-1912 Oct 2021, 12:57PM Everest Organics submits share transfer audit certificate6 Oct 2021, 5:00PM Everest Organics informs about issuance of duplicate share certificate17 Sep 2021, 5:19PM Everest Organics informs about issuance of duplicate share certificate18 Aug 2021, 10:48AM Everest Organics informs about newspaper advertisements 13 Aug 2021, 3:38PM Everest Organics informs about newspaper publication5 Jun 2021, 2:11PM Everest Organics develops anti-fungal API ‘Posaconazole’25 May 2021, 9:55AM Everest Organics informs about compliance certificate5 Apr 2021, 4:12PM Everest Organics informs about disclosure19 Feb 2021, 11:49AM Everest Organics board approves unaudited financial results8 Feb 2021, 4:12PM Everest Organics receives temporary closure orders for Telangana unit8 Jan 2021, 10:58AM Everest Organics informs about loss of share certificate23 Dec 2020, 4:09PM Everest Organics informs about loss of share certificate22 Sep 2020, 3:18PM Everest Organics develops Remdesivir API 10 Aug 2020, 12:24PM Everest Organics informs about board meeting18 Jun 2020, 3:32PM

Everest Organics Stock Price Analysis and Quick Research Report. Is Everest Organics an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Everest Organics and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Everest Organics cash from the operating activity was Rs 18.4156 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Everest Organics has a Debt to Equity ratio of 1.1046 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Everest Organics , the EPS growth was -115.934527140459 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Everest Organics has OPM of 0.507953087817211 % which is a bad sign for profitability.
     
  • ROE: Everest Organics have a poor ROE of -0.391777826278143 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Everest Organics is Rs 136.25. One can use valuation calculators of ticker to know if Everest Organics share price is undervalued or overvalued.
Last Updated on:
Brief about Everest Organics
X